Country: Canada
Language: English
Source: Health Canada
CALCITONIN (SALMON SYNTHETIC)
STERIMAX INC
H05BA01
CALCITONIN (SALMON SYNTHETIC)
200UNIT
SOLUTION
CALCITONIN (SALMON SYNTHETIC) 200UNIT
INTRAMUSCULAR
100
Prescription
PARATHYROID AND ANTIPARATHYROID AGENTS
Active ingredient group (AIG) number: 0111011001; AHFS:
APPROVED
2023-02-20
PRODUCT MONOGRAPH PR CALCITONIN (SALMON) INJECTION, BP 400 IU / 2 ML (200 IU / ML) STERILE SOLUTION FOR INTRAMUSCULAR OR SUBCUTANEOUS INJECTION SYNTHETIC SALMON CALCITONIN CALCIUM REGULATOR Submission Control No.: 271424 Date of Preparation: FEB 15, 2023 SteriMax Inc. 2770 Portland Drive Oakville, Ontario L6H 6R4 - 2 - PRODUCT MONOGRAPH Pr Calcitonin (Salmon) Injection, BP 400 IU / 2 mL (200 IU / mL) THERAPEUTIC CLASSIFICATION Synthetic salmon calcitonin Calcium Regulator ACTIONS Calcitonin participates in the regulation of the homeostasis of calcium by acting primarily on the bone: in Paget's disease presumably by an initial blocking effect on accelerated bone resorption. The rate of bone turnover appears to be decreased. Calcitonin participates in the regulation of urinary excretion of phosphate and calcium. Administration of calcitonin decreases the volume and acidity of the gastric juice and decreases the volume as well as trypsin and amylase content of the pancreatic juice. (For further details see CLINICAL PHARMACOLOGY section). INDICATIONS 1) Paget's Disease Treatment of symptomatic Paget's disease only in patients who do not respond to alternative treatments or for whom such treatments are not suitable. 2) Hypercalcemia Early treatment of hypercalcemic emergencies, along with other appropriate agents, when a rapid decrease in serum calcium is required, until more specific treatment of the underlying disease can be accomplished. It also may be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide, oral phosphate or corticosteroids, or other agents. Calcitonin may be used in patients with azotemia and those with limited cardiac reserve in whom intravenous fluids may be contraindicated. Due to evidence of an increased risk of malignancies with the long-term calcitonin use, the treatment duration should be limited to the shortest period of time possible and using the minimum effective dose. - 3 - CONTRAINDICATIONS Patients who are hypersensitive to this drug or to Read the complete document